ME02871B - Postupak za ćelijsku ekspresiju rnk - Google Patents
Postupak za ćelijsku ekspresiju rnkInfo
- Publication number
- ME02871B ME02871B MEP-2017-217A MEP21717A ME02871B ME 02871 B ME02871 B ME 02871B ME P21717 A MEP21717 A ME P21717A ME 02871 B ME02871 B ME 02871B
- Authority
- ME
- Montenegro
- Prior art keywords
- cells
- pkr
- rna
- fibroblasts
- expression
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 14
- 230000014509 gene expression Effects 0.000 title claims 6
- 108091092328 cellular RNA Proteins 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims 14
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 claims 10
- 210000002950 fibroblast Anatomy 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 210000000130 stem cell Anatomy 0.000 claims 5
- 210000001082 somatic cell Anatomy 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 3
- 230000002708 enhancing effect Effects 0.000 claims 3
- VFBGXTUGODTSPK-BAQGIRSFSA-N (8z)-8-(1h-imidazol-5-ylmethylidene)-6h-pyrrolo[2,3-g][1,3]benzothiazol-7-one Chemical group O=C1NC2=CC=C3N=CSC3=C2\C1=C\C1=CN=CN1 VFBGXTUGODTSPK-BAQGIRSFSA-N 0.000 claims 1
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 claims 1
- 102100039247 ETS-related transcription factor Elf-4 Human genes 0.000 claims 1
- 101000813135 Homo sapiens ETS-related transcription factor Elf-4 Proteins 0.000 claims 1
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 claims 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 claims 1
- 102100025460 Protein lin-28 homolog A Human genes 0.000 claims 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000035578 autophosphorylation Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000018109 developmental process Effects 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 102000010982 eIF-2 Kinase Human genes 0.000 claims 1
- 108010037623 eIF-2 Kinase Proteins 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000008672 reprogramming Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Claims (12)
1. Postupak za dobijanje ćelija koje imaju karakteristike matičnih ćelija in vitro koji oobuhvata korake (i) smanjenja aktivnosti od RNK zavisne kinaze proteina (PKR) u populaciji ćelija koja obuhvata somatske ćelije, (ii) uvođenje RNK koja može da ispoljava jedan ili više faktora koji omogućavaju reprogramiranje somatskih ćelija u ćelije koje imaju karakteristike matičnih ćelija u barem deo somatskih ćelija, i (iii) omogućavanje razvoja ćelija koje imaju karakteristike matične ćelije.
2. Postupak iz patentnog zahtjeva 1, pri čemu jedan ili više činilaca obuhvata OCT4 i SOX2.
3. Postupak iz patentnog zahtjeva 2, pri čemu jedan ili više činilaca obuhvata ELF4 i/ili c-MYC i/ili NANOG i/ili LIN28.
4. Postupak iz jednog ili više patentnih zahtjeva 1 do 3, pri čemu korak smanjenja aktivnosti PKR u ćelijama daje kao rezultat pospešivanje stabilnosti i/ili pospešivanje ekspresije RNK u tim ćelijama.
5. Postupak iz patentnog zahteva 4, pri čemu pospešivanje ekspresije RNK u tim ćelijama obuhvata povećanje nivoa ekspresije i/ili povećanje trajanja ekspresije RNK u tim ćelijama.
6. Postupak iz bilo kog od patentnih zahtjeva 1 do 5, pri čemu korak smanjenja aktivnosti PKR u ćelijama obuhvata tretiranje ćelija barem jednim PKR inhibitorom ili prigušivanje ekspresije PKR gena.
7. Postupak iz patentnog zahtjeva 6, pri čemu PKR inhibitor suzbija sa RNK indukovanu PKR autofosforilaciju.
8. Postupak iz patentnog zahtjeva 6 ili 7, pri čemu PKR inhibitor jeste jedinjenje imidazolo-oksindola, 2-aminopurin ili virusno izveden inhibitor PKR.
9. Postupak iz patentnog zahtjeva 8, pri čemu pomenuti imidazolo-oksindol jeste 6,8-dihidro-8-(1H imidazol-5-ilmetilen)-7H-pirolo[2,3-g]benzotiazol-7-on i pri čemu se virusno izveden inhibitor PKR bira iz grupe koja obuhvata virus za vakcinu E3 i/ili K3, ili njihov RNK.
10. Postupak iz bilo kog od patentnih zahtjeva 1 do 9, pri čemu somatske ćelije jesu fibroblasti.
11. Postupak iz patentnog zahtjeva 10, pri čemu pomenuti fibroblasti jesu fibroblasti pluća, fibroblasti prepucijuma ili dermalni fibroblasti.
12. Postupak za dobijanje diferenciranih tipova ćelije obuhvata korake (i) dobijanja ćelija koje imaju karakteristike matične ćelije korišćenjem postupka iz bilo kog od patentnih zahteva 1 do 11, i (ii) kultivacije ćelija koje imaju karakteristike matične ćelije pod uslovima koji indukuju ili usmeravaju delimičnu ili potpunu diferencijaciju u diferencirani tip ćelije.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2010/007362 WO2012072096A1 (en) | 2010-12-03 | 2010-12-03 | Method for cellular rna expression |
| EP11791447.3A EP2646557B1 (en) | 2010-12-03 | 2011-12-02 | Method for cellular rna expression |
| PCT/EP2011/006061 WO2012072269A1 (en) | 2010-12-03 | 2011-12-02 | Method for cellular rna expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02871B true ME02871B (me) | 2018-04-20 |
Family
ID=45644286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-217A ME02871B (me) | 2010-12-03 | 2011-12-02 | Postupak za ćelijsku ekspresiju rnk |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP2646557B1 (me) |
| CY (1) | CY1119355T1 (me) |
| HR (1) | HRP20171393T1 (me) |
| ME (1) | ME02871B (me) |
| PL (1) | PL2646557T3 (me) |
| RS (1) | RS56419B1 (me) |
| SI (1) | SI2646557T1 (me) |
| SM (1) | SMT201700446T1 (me) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL126757A0 (en) * | 1998-09-07 | 1999-08-17 | Yissum Res Dev Co | Regulation of gene expression through manipulation of mRNA splicing and its uses |
| EP1309726B2 (en) | 2000-03-30 | 2018-10-03 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
| GB0104948D0 (en) * | 2001-02-28 | 2001-04-18 | Novartis Res Foundation | Novel methods |
| RU2522001C2 (ru) * | 2008-10-31 | 2014-07-10 | Сентокор Орто Байотек Инк. | Дифференцирование человеческих эмбриональных стволовых клеток в линию панкреатических эндокринных клеток |
| WO2012072096A1 (en) * | 2010-12-03 | 2012-06-07 | Biontech Ag | Method for cellular rna expression |
-
2011
- 2011-12-02 ME MEP-2017-217A patent/ME02871B/me unknown
- 2011-12-02 EP EP11791447.3A patent/EP2646557B1/en active Active
- 2011-12-02 PL PL11791447T patent/PL2646557T3/pl unknown
- 2011-12-02 RS RS20170940A patent/RS56419B1/sr unknown
- 2011-12-02 SI SI201131281T patent/SI2646557T1/sl unknown
- 2011-12-02 SM SM20170446T patent/SMT201700446T1/it unknown
- 2011-12-02 HR HRP20171393TT patent/HRP20171393T1/hr unknown
- 2011-12-02 EP EP17182410.5A patent/EP3282015B1/en active Active
-
2017
- 2017-09-20 CY CY20171100987T patent/CY1119355T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SMT201700446T1 (it) | 2017-11-15 |
| CY1119355T1 (el) | 2018-02-14 |
| EP3282015A2 (en) | 2018-02-14 |
| RS56419B1 (sr) | 2018-01-31 |
| EP2646557B1 (en) | 2017-08-09 |
| EP3282015B1 (en) | 2020-05-20 |
| EP2646557A1 (en) | 2013-10-09 |
| EP3282015A3 (en) | 2018-02-21 |
| PL2646557T3 (pl) | 2017-12-29 |
| SI2646557T1 (sl) | 2017-11-30 |
| HRP20171393T1 (hr) | 2017-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | microRNAs modulate iPS cell generation | |
| PT2646557T (pt) | Método para expressão de arn celular | |
| Rony et al. | Inducing pluripotency in vitro: recent advances and highlights in induced pluripotent stem cells generation and pluripotency reprogramming | |
| WO2009061442A8 (en) | Method to produce induced pluripotent stem (ips) cells form non-embryonic human cells | |
| WO2007127927A3 (en) | Differentiation of human embryonic stem cells | |
| RU2014127505A (ru) | Способы и препараты для трансфекции клеток | |
| AU2013403885B2 (en) | Method for differentiating pluripotent stem cell induced from mesenchymal stem cell into hepatocyte | |
| Ghasemi‐Dehkordi et al. | Comparison between the cultures of human induced pluripotent stem cells (hiPSCs) on feeder‐and serum‐free system (Matrigel matrix), MEF and HDF feeder cell lines | |
| WO2004087885A3 (en) | Method for transdifferentiation of non-pancreatic stem cells to the pancreatic pathway | |
| JP2011068660A5 (me) | ||
| RU2015131279A (ru) | Композиции клеток, полученные из дедифференцированных перепрограммированных клеток | |
| NZ600068A (en) | Multipotent stem cells from the extrahepatic billary tree and methods of isolating same | |
| WO2014201254A1 (en) | Methods for maturing cardiomyocytes and uses thereof | |
| US9994820B2 (en) | Method for differentiating pluripotent stem cell induced from mesenchymal stem cell into chondrocyte | |
| EP1679964A4 (en) | COMPOSITIONS AND METHODS USING ARNS, AMPHIPATHIC COMPOUNDS AND POLYCATIONS | |
| US20230138022A1 (en) | Methods of making pluripotent stem cells and uses thereof | |
| US20160272939A1 (en) | Method for Differentiating Pluripotent Stem Cell Induced from Mesenchymal Stem Cell Into Neuron | |
| CN104673741B (zh) | 高效非整合性人类iPSC诱导平台 | |
| ATE466075T1 (de) | Neue dehydrogenasen, deren derivate und ein verfahren zur herstellung von optisch aktiven alkanolen | |
| ME02871B (me) | Postupak za ćelijsku ekspresiju rnk | |
| US20190177696A1 (en) | Method for preparing induced hepatic progenitor cells | |
| US10494603B2 (en) | Method for differentiating a pluripotent stem cell induced from a mesenchymal stem cell into an adipocyte | |
| US20220356451A1 (en) | Methods to reprogram somatic cells to alternative cell fates or primitive cell states | |
| Ma et al. | Development of a human induced pluripotent stem cell (iPSC) line from a Parkinson's disease patient carrying the N551K variant in LRRK2 gene | |
| Ma et al. | Reprogramming of a human induced pluripotent stem cell (iPSC) line from a Parkinson's disease patient with a R1628P variant in the LRRK2 gene |